Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H15N7O |
Molar mass | 345.366 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
SCH-58261 is a drug which acts as a potent and selective antagonist for the adenosine receptor A2A, with more than 50x selectivity for A2A over other adenosine receptors.[1] It has been used to investigate the mechanism of action of caffeine, which is a mixed A1 / A2A antagonist, and has shown that the A2A receptor is primarily responsible for the stimulant and ergogenic effects of caffeine,[2] but blockade of both A1 and A2A receptors is required to accurately replicate caffeine's effects in animals.[3][4][5][6] SCH-58261 has also shown antidepressant,[7] nootropic and neuroprotective effects in a variety of animal models,[8][9][10][11][12][13] and has been investigated as a possible treatment for Parkinson's disease.[14][15]
Receptor (ligands) |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (blockers) |
| ||||||||||
Enzyme (inhibitors) |
| ||||||||||
Others | |||||||||||
See also: Receptor/signaling modulators |